Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.

Mehta A, Forero-Torres A.

Curr Oncol Rep. 2015 Sep;17(9):41. doi: 10.1007/s11912-015-0466-9. Review.

PMID:
26194424
2.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F.

Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.

PMID:
25925619
3.

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.

Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.

Expert Opin Investig Drugs. 2015;24(7):897-912. doi: 10.1517/13543784.2015.1038342. Epub 2015 Apr 21. Review.

PMID:
25900401
4.

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.

Merli M, Ferrario A, Maffioli M, Olivares C, Stasia A, Arcaini L, Passamonti F.

Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14. Review.

PMID:
27416486
5.

Antibody-drug conjugates: present and future.

Beck A, Reichert JM.

MAbs. 2014 Jan-Feb;6(1):15-7. doi: 10.4161/mabs.27436.

PMID:
24423577
6.

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

Lambert JM, Morris CQ.

Adv Ther. 2017 May;34(5):1015-1035. doi: 10.1007/s12325-017-0519-6. Epub 2017 Mar 30. Review.

7.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
8.

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.

Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK.

Pharmacotherapy. 2013 Jan;33(1):93-104. doi: 10.1002/phar.1170. Review.

PMID:
23307550
9.

Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

Mei M, Thomas S, Chen R.

BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7. Review.

10.

Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.

Jerjian TV, Glode AE, Thompson LA, O'Bryant CL.

Pharmacotherapy. 2016 Jan;36(1):99-116. doi: 10.1002/phar.1687. Review.

PMID:
26799352
11.

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.

Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, Polakis P, Flygare J, Polson AG.

Clin Cancer Res. 2015 Jul 15;21(14):3298-306. doi: 10.1158/1078-0432.CCR-14-2035. Epub 2015 Apr 3.

12.

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Advani RH, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, Agarwal P, Dere RC, Hsieh HJ, Jones S, Chu YW, Cheson BD.

Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. doi: 10.1158/1078-0432.CCR-16-0772. Epub 2016 Sep 6.

13.

Brentuximab vedotin.

Deng C, Pan B, O'Connor OA.

Clin Cancer Res. 2013 Jan 1;19(1):22-7. doi: 10.1158/1078-0432.CCR-12-0290. Epub 2012 Nov 15. Review.

14.

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Senter PD, Sievers EL.

Nat Biotechnol. 2012 Jul 10;30(7):631-7. doi: 10.1038/nbt.2289.

PMID:
22781692
15.

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.

Ricart AD.

Clin Cancer Res. 2011 Oct 15;17(20):6417-27. doi: 10.1158/1078-0432.CCR-11-0486. Review.

16.

Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F.

Crit Rev Oncol Hematol. 2017 Jan;109:42-50. doi: 10.1016/j.critrevonc.2016.11.009. Epub 2016 Nov 21. Review.

17.

Anti-CD30 Antibodies for Hodgkin lymphoma.

Foyil KV, Bartlett NL.

Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y. Review.

PMID:
20446121
18.

Drug-conjugated antibodies for the treatment of cancer.

Lambert JM.

Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Review.

19.

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.

Alperovich A, Younes A.

Cancer J. 2016 Jan-Feb;22(1):23-6. doi: 10.1097/PPO.0000000000000168. Review.

20.

CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Bhatt G, Maddocks K, Christian B.

Curr Hematol Malig Rep. 2016 Dec;11(6):480-491. doi: 10.1007/s11899-016-0345-y. Review.

PMID:
27613003

Supplemental Content

Support Center